drugset

Drugs / Botulinum type A

Follow last change Oct 2021 re-read 3 minutes ago

Botulinum type A

also known as botulinum toxin type A · BTX-A

Investigated by: Peking University

Trials 2

today NCT05127018 · Ph 1/2 NCT04820543 · Ph 4

20192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT05127018	Nov 2019 → Aug 2020	—	Peking University	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT04820543	Feb → Nov 2019	salivary substance, Clostridium botulinum type	Peking University	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2020-01-06	Ipsen	Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy ipsen.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Botulinum type A	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04820543 ↗ 1 NCT05127018 ↗
Known as	botulinum toxin type A	“botulinum toxin type A (BTX-A) treatment is an easy and fast outpatient procedure” NCT04820543 ↗
Known as	BTX-A	“Botulinum type A (BTX-A) is an easy and efficacious treatment for gingival smile (GS).” NCT04820543 ↗